These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26827076)

  • 1. Primary progressive multiple sclerosis--why we are failing.
    Segal BM; Stüve O
    Lancet; 2016 Mar; 387(10023):1032-1034. PubMed ID: 26827076
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple sclerosis: Fingolimod failure in progressive MS INFORMS future trials.
    Smith AL; Cohen JA
    Nat Rev Neurol; 2016 May; 12(5):253-4. PubMed ID: 27020561
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in vital signs after fingolimod initiation in patients with multiple sclerosis: the possible need for 24 h monitoring.
    Tomohiko U; Mori M; Akiyuki U; Masuda S; Mutho M; Masuda H; Kuwabara S
    Br J Clin Pharmacol; 2015 Sep; 80(3):607-8. PubMed ID: 26077133
    [No Abstract]   [Full Text] [Related]  

  • 5. Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.
    Davion JB; Cambron M; Duhin E; Chouraki A; Lacour A; Labauge P; Carra C; Ayrignac X; Vermersch P
    J Neurol; 2016 Jul; 263(7):1361-3. PubMed ID: 27159986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
    Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
    J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
    [No Abstract]   [Full Text] [Related]  

  • 7. Sometimes less is more in multiple sclerosis drug switching.
    Costa BK; Sato DK
    Arq Neuropsiquiatr; 2016 Aug; 74(8):605-6. PubMed ID: 27556369
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis.
    Fragoso YD; Alves-Leon SV; Becker J; Brooks JB; Correa EC; Damasceno A; Gama PD; Gama RA; Matta AP; Maciel EP; Winckler TC
    Arq Neuropsiquiatr; 2016 Aug; 74(8):650-2. PubMed ID: 27556377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
    Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
    Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.
    Thomas K; Proschmann U; Ziemssen T
    Expert Opin Pharmacother; 2017 Oct; 18(15):1649-1660. PubMed ID: 28844164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
    Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
    Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use.
    Thoo S; Cugati S; Lee A; Chen C
    Mult Scler; 2015 Feb; 21(2):249-51. PubMed ID: 24696055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tp-Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis.
    Tocci G; Giuliani M; Canichella F; Timpano J; Presta V; Francia P; Musumeci MB; Fubelli F; Pozzilli C; Volpe M; Ferrucci A
    Int J Cardiol; 2016 Oct; 221():881-5. PubMed ID: 27434365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Fox E; Edwards K; Burch G; Wynn DR; LaGanke C; Crayton H; Hunter SF; Huffman C; Kim E; Pestreich L; McCague K; Barbato L;
    Mult Scler Relat Disord; 2014 Sep; 3(5):607-19. PubMed ID: 26265273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy.
    Fujii C; Kondo T; Ochi H; Okada Y; Hashi Y; Adachi T; Shin-Ya M; Matsumoto S; Takahashi R; Nakagawa M; Mizuno T
    Sci Rep; 2016 Oct; 6():35314. PubMed ID: 27752051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
    Warrender-Sparkes M; Spelman T; Izquierdo G; Trojano M; Lugaresi A; Grand'Maison F; Havrdova E; Horakova D; Boz C; Oreja-Guevara C; Alroughani R; Iuliano G; Duquette P; Girard M; Terzi M; Hupperts R; Grammond P; Petersen T; Fernandez-Bolaños R; Fiol M; Pucci E; Lechner-Scott J; Verheul F; Cristiano E; Van Pesch V; Petkovska-Boskova T; Moore F; Kister I; Bergamaschi R; Saladino ML; Slee M; Barnett M; Amato MP; Shaw C; Shuey N; Young C; Gray O; Kappos L; Butzkueven H; Kalincik T; Jokubaitis V;
    Mult Scler; 2016 Apr; 22(4):520-32. PubMed ID: 26199347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Hughes B; Cascione M; Freedman MS; Agius M; Kantor D; Gudesblatt M; Goldstick LP; Agashivala N; Schofield L; McCague K; Hashmonay R; Barbato L;
    Mult Scler Relat Disord; 2014 Sep; 3(5):620-8. PubMed ID: 26265274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.
    Zinger A; Latham SL; Combes V; Byrne S; Barnett MH; Hawke S; Grau GE
    Mult Scler; 2016 Dec; 22(14):1883-1887. PubMed ID: 26931477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis.
    Cursiefen S; Flachenecker P; Toyka KV; Rieckmann P
    Eur Neurol; 2000; 43(3):186-7. PubMed ID: 10765063
    [No Abstract]   [Full Text] [Related]  

  • 20. [Oral disease-modifying agents in relapsing-remitting multiple sclerosis].
    Iljicsov A; Pál Z; Simó M
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):197-205. PubMed ID: 26727724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.